Physician profile
Leon Mullen
NPI 1497831986
$2,946.37
in general payments reported to CMS, 2019-2025
14 companies · $60.14 in 2025
The $60.14 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $253 · 2021: $522 · 2022: $1,216 · 2023: $398 · 2024: $45.88 · 2025: $60.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.41 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $439.65 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $392.71 | 2022-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $319.70 | 2019-2025 | Lifevest |
| Abbott Laboratories | $233.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $224.99 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $219.88 | 2022-2023 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $214.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $159.73 | 2019-2020 | |
| Intuity Medical INC | $121.22 | 2022 | |
| Mallinckrodt Enterprises LLC | $97.00 | 2019 | |
| Gilead Sciences, INC. | $38.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.38 | 2021 | |
| Heartflow, INC. | $16.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.